Septerna Inc. (SEPN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for SEPN, including 1 insider trade and 1 press release or news item. The most recent was published Nov 3, 2026.
SEPN rankings
Financial highlights
Full financials- Revenue, TTM
- $98.88M
- Revenue growth
- +13520.1%
- Net income, TTM
- -$24.24M
- Net margin
- -24.5%
- Free cash flow, TTM
- $105.10M
- Cash
- $84.66M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks46+100%
2026-05-102026-11-01
Mix2190d
- SEC Filings7(33%)
- Insider7(33%)
- Other6(29%)
- Leadership1(5%)
Latest news
25 items- PRSepterna to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026: Guggenheim 3rd Annual Healthcare Innovation Conference – BostonFireside chat on Tuesday, November 10, 2026, at 10:00 a.m. ET Stifel 2026 Healthcare Conference – New YorkFireside chat on Wednesday, November 11, 2026, at 1:20 p.m. ET UBS Global Biopharma Conference – LondonFireside chat on Monday, November 16, 2026, at 2:00 p.m. GMT 9th Annual Evercore Healthcare Conference –
- INSIDERPresident and COO Bhatt Elizabeth sold $149,644 worth of shares (4,000 units at $37.41) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Patni Rajiv4 - Septerna, Inc. (0001984086) (Issuer)
- PRSepterna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s common stock to Rajiv Patni, M.D., the Company’s newly appointed Chief Medical Officer, under the Company’s 2026 Inducement Plan (the "Inducement Plan"). The inducement grant was effective as of September 8, 2026. The award was granted as an inducement material to Dr. Patni’s employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $37.37 per share, which is equal to the closing price of the Company’s common stock on Sept
- INSIDERSEC Form 3 filed by new insider Patni Rajiv3 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERSVP, Drug Discovery Long Daniel D. exercised 3,333 shares at a strike of $2.76 and sold $126,078 worth of shares (3,333 units at $37.83) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- PRSepterna to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September: Wells Fargo 21st Annual Healthcare ConferenceFireside chat on Tuesday, September 8, 2026, at 8:00 a.m. ET Cantor Global Healthcare Conference 2026Fireside chat on Thursday, September 10, 2026, at 11:30 a.m. ET A live webcast of each presentation will be available in the investors section of the company’s website at www.septerna.com. The webcasts will be archived for at least 30 days f
- SECSepterna Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical OfficerSOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations. "We are thrilled to welcome Rajiv to the team as we execute on our strategy to develop differentiated oral medicines targeting GPCRs," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septe
- INSIDERSEC Form 4 filed by Large owner Third Rock Ventures V, L.P.4 - Septerna, Inc. (0001984086) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Septerna Inc.SCHEDULE 13D/A - Septerna, Inc. (0001984086) (Subject)
- INSIDERDirector Ra Capital Management, L.P. sold $63,452,500 worth of shares (1,493,000 units at $42.50) (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.SCHEDULE 13G/A - Septerna, Inc. (0001984086) (Subject)
- INSIDERPresident and COO Bhatt Elizabeth exercised 25,000 shares at a strike of $5.79 and sold $1,100,000 worth of shares (25,000 units at $44.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- SECSEC Form 10-Q filed by Septerna Inc.10-Q - Septerna, Inc. (0001984086) (Filer)
- SECSepterna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Highlights Business Progress and Reports Second Quarter 2026 Financial ResultsPhase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the second quarter ended June 30, 2026. "We continue to make meaningful progress across our portfolio as we e
- INSIDERSVP, Drug Discovery Long Daniel D. sold $114,920 worth of shares (3,334 units at $34.47) as part of a pre-agreed trading plan and exercised 3,334 shares at a strike of $2.76 (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERPresident and COO Bhatt Elizabeth sold $135,974 worth of shares (4,000 units at $33.99) as part of a pre-agreed trading plan and exercised 4,000 shares at a strike of $6.81 (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- INSIDERSVP, Drug Discovery Long Daniel D. exercised 3,333 shares at a strike of $2.76 and sold $114,528 worth of shares (3,333 units at $34.36) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
SEPN FAQ
10 questionsWhat is the latest news on SEPN?
In the last 30 days Quantisnow tracked 2 wire items for SEPN: 1 insider trade and 1 press release or news item. The most recent was published on November 3, 2026.What is SEPN revenue?
Septerna Inc. (SEPN) reported $98.88M of revenue for the twelve months ended Jun 30, 2026. That is up 13520.1% from the year before. Revenue for fiscal 2025 was $45.95M.Is SEPN profitable?
No. Septerna Inc. reported a net loss of $24.24M for the twelve months ended Jun 30, 2026.How much cash and debt does SEPN have?
Septerna Inc. reported $84.66M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does SEPN stock trade?
Septerna Inc. (SEPN) is listed on NASDAQ.What sector and industry is SEPN in?
Septerna Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Septerna Inc. go public?
Septerna Inc. (SEPN) completed its IPO in 2024.What are analysts saying about SEPN?
Across the last 8 analyst actions on Septerna Inc., there were 1 upgrade and 1 downgrade. The most recent action was from Guggenheim: Buy with a $52.00 price target on 2026-06-11. Recent price targets range from $14.00 to $52.00.What companies are similar to SEPN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SEPN side-by-side with any of them on Quantisnow.How can I track SEPN on Quantisnow?
Quantisnow aggregates Septerna Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SEPN to receive live email and push alerts on every new disclosure.